Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

ConclusionsThe treatment effect of ocrelizumab versus IFN β-1a, measured by clinical and MRI outcomes, was maintained across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent with that from the pooled OPERA studies.

http://link.springer.com/10.1007/s00415-019-09248-6

Source: Journal of Neurology - April 16, 2019 Category: Neurology Source Type: research